rs6974491 — ELMO1
Intronic ELMO1 variant acting as an eQTL that modulates engulfment and cell motility protein expression in thymic and peripheral immune cells, with GWAS associations with celiac disease, primary biliary cholangitis, and inflammatory bowel disease
Details
- Gene
- ELMO1
- Chromosome
- 7
- Risk allele
- A
- Clinical
- Risk Factor
- Evidence
- Moderate
Population Frequency
Category
IBD & Mucosal ImmunitySee your personal result for ELMO1
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
ELMO1 — When the Immune System's Cleanup Crew Goes Awry
Your immune system is not just a fighting force — it is also a meticulous cleanup operation. Dead and damaged
cells must be recognized and engulfed efficiently to prevent their contents from triggering inflammation.
ELMO1 (Engulfment and Cell Motility 1) is a central coordinator of this process, working within the gut
epithelium and phagocytic immune cells to sense bacteria, orchestrate cytoskeletal changes needed for
cell engulfment, and regulate the inflammatory signals that follow. The rs6974491 variant lies deep in
ELMO1's first intron and, while it does not change the protein sequence, it acts as an expression
quantitative trait locus11 expression
quantitative trait locus
An eQTL is a DNA variant that affects how much of a protein is made, rather
than the protein's structure; the same amount of damage can be done by reducing the amount of a protein
as by impairing its function — a regulatory tuning knob
that alters ELMO1 expression in thymic and peripheral immune tissues.
ELMO1 operates as part of a conserved complex with DOCK180, together activating the small GTPase Rac122 small GTPase Rac1
Rac1 is a molecular switch that triggers the cytoskeletal rearrangements needed for a cell to extend
its membrane around a target and engulf it — the physical machinery of
phagocytosis. This Rac1 activation drives lamellipodia
formation, enabling immune cells to migrate toward signals of tissue damage and to physically engulf
apoptotic cells and invading bacteria. When ELMO1 function is disrupted, cells cannot reliably complete
this engulfment step — leaving cellular debris and bacteria uncleared, and triggering cascades that sustain
inflammation long after the initial stimulus.
The Mechanism
rs6974491 sits at position c.78+7707 in ELMO1's first intron — approximately 7,700 nucleotides downstream of
exon 1. ELMO1 is transcribed from the minus (antisense) strand33 minus (antisense) strand
The minus strand runs in the opposite
direction to the plus strand used as the genomic coordinate reference; genome files report plus-strand
alleles, so G is the reference base and A is the risk allele at this position on chromosome 7,
so the transcript notation is C>T while the genome file (plus-strand) reports G>A.
The A allele (plus strand) functions as an intronic regulatory variant influencing ELMO1 expression
levels. An eQTL study in 42 thymic tissue samples44 An eQTL study in 42 thymic tissue samples
Amundsen et al. examined 24 chromosomal regions
carrying celiac disease SNPs for effects on thymic gene expression, identifying rs6974491-ELMO1 among
nine probe-SNP pairs that replicated across both thymus and peripheral blood mononuclear
cells demonstrated that rs6974491 consistently modulates
ELMO1 expression in immune-relevant tissues — the thymus (where T cells are educated to distinguish
self from non-self) and PBMCs (the primary immune effectors in blood).
The downstream consequence operates through two converging pathways. In gut epithelial cells, ELMO1
facilitates bacterial internalization and MCP-1 secretion55 bacterial internalization and MCP-1 secretion
MCP-1 (monocyte chemoattractant protein 1)
recruits circulating monocytes to sites of infection; its dysregulation either fails to clear pathogens
or sustains excessive recruitment that drives chronic inflammation.
In chronic inflammation, ELMO1 also regulates intestinal cellular senescence: ELMO1 stabilizes SIRT1
deacetylase activity, which prevents hyperacetylation of NF-κB's p65 subunit and the cellular
senescence cascade that drives IBD-associated fibrosis66 IBD-associated fibrosis.
Reduced ELMO1 expression from the A allele may therefore impair both bacterial clearance and the
brake on NF-κB-mediated chronic inflammation.
ELMO1 also interacts directly with NOD277 NOD2
NOD2 is an intracellular pattern recognition receptor that
detects bacterial muramyl dipeptide — loss-of-function NOD2 mutations are among the strongest known
Crohn's disease risk factors, binding through its C-terminal
region to the NOD2 leucine-rich repeat domain. This physical interaction places ELMO1 in the same
innate immune sensing circuit as the most established Crohn's disease risk gene.
The Evidence
The primary evidence for rs6974491's clinical relevance comes from multiple independent GWAS streams.
The Dubois et al. 2010 celiac disease GWAS88 Dubois et al. 2010 celiac disease GWAS
4,533 celiac cases and 10,750 controls; the study identified
13 new genome-wide-significant loci with ELMO1 among genes functionally relevant to the identified
regions established rs6974491 as a celiac disease susceptibility
signal (P < 5×10⁻⁸, OR ~1.25, 95% CI 1.16–1.36 per A allele). Notably, the study found that 52% of
the identified celiac loci had variants correlated with cis-gene expression, consistent with rs6974491's
eQTL mechanism.
The Mells et al. 2011 primary biliary cirrhosis GWAS99 Mells et al. 2011 primary biliary cirrhosis GWAS
1,840 PBC cases and 5,163 UK population controls;
12 new susceptibility loci identified independently identified
rs6974491 among susceptibility loci for a separate autoimmune condition — primary biliary cholangitis
(PBC), an autoimmune liver disease caused by destruction of intrahepatic bile ducts. The replication
of the same variant across celiac disease and PBC underscores that rs6974491 likely affects a shared
mechanism of immune self-tolerance rather than organ-specific pathology.
The Parmar et al. 2012 IBD meta-analysis1010 Parmar et al. 2012 IBD meta-analysis
699 Finnish IBD patients and 2,482 controls, with Swedish UC
replication; 45 genetic markers tested for celiac disease-IBD
overlap found particularly strong effects in pediatric
ulcerative colitis (OR 2.20, P=0.0002) and familial UC (OR 1.73, P=0.00052) — suggesting that the
variant's impact on immune regulation is most visible in early-onset and familial disease forms, where
genetic effects are proportionally larger.
The 2023 trans-ancestry Bayesian meta-analysis1111 2023 trans-ancestry Bayesian meta-analysis
43,324 IBD cases and 57,206 controls across European,
East Asian, and African American cohorts using MANTRA Bayesian analysis
confirmed ELMO1 as an IBD risk locus across multiple ancestries, though the ELMO1 A allele frequency
is extremely low in East Asian populations (< 0.5%), making European-ancestry findings the primary
evidence base. The East Asian rarity of the A allele is notable — it makes the allele's disease
associations almost exclusively a European-population story.
Practical Actions
The A allele modestly increases risk for gluten-triggered gut inflammation, IBD, and autoimmune conditions involving disrupted mucosal immunity. For GG carriers — the vast majority of the population — ELMO1 function is intact by default. For carriers of one or two A alleles, the most actionable implications concern early symptom recognition in celiac disease and IBD, and supporting the gut mucosal immune environment through specific dietary approaches.
Interactions
ELMO1 interacts directly with NOD2 (rs2066844, rs2066845, rs2066847 — common Crohn's disease variants); ELMO1 binds the NOD2 LRR domain and amplifies its bacterial sensing response. Carriers of both rs6974491-A and NOD2 loss-of-function alleles may have a compounded impairment in bacterial muramyl dipeptide sensing and clearance. Additionally, ELMO1 cooperates with DOCK180 (encoded by DOCK1) through direct physical interaction — the ELMO1/DOCK180 GEF complex is the upstream activator of Rac1, so variants affecting ELMO1 expression may compound with DOCK180 functional variants.
Genotype Interpretations
What each possible genotype means for this variant:
Common genotype with normal ELMO1 expression — standard immune clearance capacity
You carry two copies of the reference G allele at rs6974491, the most common genotype. This indicates normal ELMO1 regulatory function at this intronic locus: your ELMO1 expression in thymic tissue and peripheral blood immune cells is not altered by this variant. Approximately 69% of people of European descent share this GG genotype. Your baseline risk for celiac disease, IBD, and primary biliary cholangitis from this variant specifically is at population-average level. Note that overall risk for these conditions depends on many other genetic and environmental factors, including HLA haplotypes which carry far larger effects for celiac disease.
One A allele modestly reduces ELMO1 activity in immune tissues — slightly elevated risk for gut autoimmunity
The clinical picture for AG carriers spans multiple autoimmune conditions with shared mucosal immune architecture. ELMO1 is expressed in intestinal epithelial cells and macrophages where it coordinates bacterial engulfment and NF-κB-regulated inflammatory signaling via SIRT1/p65. Reduced ELMO1 expression may impair the MCP-1-mediated monocyte recruitment pathway following bacterial invasion and may destabilize the SIRT1-mediated brake on cellular senescence, both of which contribute to chronic gut inflammation. The thymic eQTL effect (Amundsen et al. 2014) suggests a role in T-cell education as well — thymic ELMO1 expression may influence self-tolerance mechanisms that underlie susceptibility to celiac disease, which is fundamentally a T-cell-mediated response to gluten peptides.
Two A alleles substantially reduce ELMO1 expression in immune tissues — elevated risk for gut autoimmunity
The mechanistic basis for elevated risk in AA homozygotes spans several pathways. First, ELMO1 expression is reduced bi-directionally in the thymus, where self-tolerance is established; thymic ELMO1 expression may be important for efficient clearance of apoptotic thymocytes during negative selection, and its reduction could allow self-reactive T cells to escape deletion. Second, in gut epithelial cells, reduced ELMO1 impairs both bacterial internalization (via the DOCK180-ELMO1-Rac1 GEF complex) and the SIRT1-mediated NF-κB brake, creating a dual vulnerability: slower clearance of gut bacteria combined with a reduced ability to terminate the inflammatory response once initiated. Third, the ELMO1-NOD2 physical interaction suggests that AA carriers may have reduced sensitivity to muramyl dipeptide (bacterial cell wall component), the primary NOD2 ligand — a pattern functionally similar to the NOD2 loss-of-function mutations that are the strongest known Crohn's disease genetic risk factors.
The combination of these mechanisms makes AA carriers the subgroup for whom proactive celiac antibody testing, IBD symptom awareness, and dietary support of gut barrier integrity are most warranted.